For years, clinical research trial protocols rarely thought about the patient experience as an element to inform the study design. Discover why clinical trials are now becoming more participant-friendly (and more provider-friendly) through the broader adoption of digital technologies.
As technology evolves, the adoption of mobile and digital devices and platforms in trial design represents a critical point in the continuum of clinical trial development. However, it’s not an ultimate destination. Learn how the goal of decentralization should be to optimize and streamline clinical trials versus moving traditional workarounds.
While complex trials are important to getting treatments to market faster, they are becoming more challenging to design and conduct. In this on-demand webinar, Merative and MMS Holdings discuss their experience managing advanced adaptive trial intricacy and how a unified data management and acquisition platform is essential to that success.
The industry has looked to decentralized clinical trials to be more inclusive and to accommodate patients that are commuting long distances or unable to take off work to visit a clinical site. Consider the risks of remotely collected data, increased trial participants, and other notable points when questioning if decentralization is the answer to democratizing clinical trials.
Zelta (formerly Merative Clinical Development) has more than a decade of logged vision, innovation, and success. Discover how Zelta can help you accelerate clinical trials with unmatched control and confidence.
Learn about Merative’s new clinical trial solutions business Zelta, which includes both a clinical data management and acquisition platform (formerly Merative Clinical Development), consulting, enablement, and extension services.
